Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-142 QT/QTc Study in Healthy Adults
NCT04873323Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vornorexant in Insomnia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: QT-interval corrected by Fridericia. Started Jun 2021; status: completed.
02
Drugs
vornorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04873323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04873323.